6533b7d8fe1ef96bd126af65

RESEARCH PRODUCT

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal

Renzo MazzarottoAlexander HaugCarlo Ludovico MainiRaquel Sánchez VaňóJuan Antonio Vallejo CasasFabio MonariRosa SciutoElisa Caballero CalabuigFernando RodriguesJames MagnerMichela BassoThorsten PetrichMarcelino Gómez BalaguerPeter BartensteinM. Angustias Muros De FuentesFederica Vianello

subject

AdultMalemedicine.medical_specialtyNeoplasm ResidualEndocrinology Diabetes and Metabolismmedicine.medical_treatmentUrologyRemnant ablationIodine RadioisotopesYoung AdultEndocrinologyClinical endpointmedicineHumansThyroid NeoplasmsThyrotropin AlfaThyroid cancerAgedRetrospective StudiesAged 80 and overHigh risk patientsbusiness.industryThyroidCancerMiddle Agedmedicine.diseaseAblationCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureThyroidectomyFemalebusinessHormone

description

Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule).A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received (131)I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since January 2000 (rhTSH n=74, THW n=70). The primary endpoint was based on evaluation of diagnostic radioiodine scan thyroid bed uptake more than six months after the ablation procedure, while stimulated serum Tg was a secondary endpoint. Safety was evaluated within 30 days after rhTSH or (131)I.Successful ablation judged by scan was achieved in 65/70 (92.9%) of rhTSH and in 61/67 (91.0%) of THW patients; the success rates were comparable, since noninferiority criteria were met. Although some patients in the initial cohort had tumor in cervical nodes and metastases, considering all evaluable patients regardless of various serum anti-Tg antibody assessments, the stimulated Tg was2 ng/mL in 48/70 (68.6%) and 39/67 (58.2%) in rhTSH and THW groups respectively; if patients with anti-Tg antibody levels30 IU/mL were excluded, the stimulated Tg was2 ng/mL in 42/62 (67.7%) and 37/64 (57.8%) respectively. No serious adverse events occurred within the 30-day window after ablation.Use of rhTSH as preparation for thyroid remnant ablation in patients with T4 primary tumors achieved a rate of ablation success that was high and noninferior to the rate seen after THW, and rhTSH was well tolerated.

https://doi.org/10.1089/thy.2013.0157